Wayne Ghesquière

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Anthony L. Cunningham, Himal Lal, Martina Kovac et al. · New England Journal of Medicine · 2016 · 1K citations · Full text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 299 citations

Open-label Phase 2, Hepatology, Hepatitis C +10

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

Andrew J. Muir, Fred Poordad, Jacob Lalezari et al. · JAMA · 2015 · 126 citations · Full text

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Christophe Hézode, Gideon M. Hirschfield, Wayne Ghesquière et al. · Gut · 2014 · 118 citations

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo et al. · Clinical Infectious Diseases · 2021 · 90 citations · Full text